Spots Global Cancer Trial Database for autologous hematopoietic stem cell transplantation

Every month we try and update this database with for autologous hematopoietic stem cell transplantation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma	NCT01476839	Recurrent Adult...	basiliximab carmustine etoposide cytarabine melphalan pharmacological... laboratory biom... autologous hema... yttrium Y 90-la...	18 Years - 70 Years	City of Hope Medical Center
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma	NCT01527149	Stage I Mantle ... Stage II Contig... Stage II Non-Co... Stage III Mantl... Stage IV Mantle...	Autologous Hema... Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul...	18 Years - 70 Years	Roswell Park Cancer Institute
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma	NCT00450827	Neuroblastoma	bevacizumab filgrastim autologous hema... iodine I 131 mo...	1 Year -	Memorial Sloan Kettering Cancer Center
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant	NCT00114101	DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult...	Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis...	18 Years - 70 Years	National Cancer Institute (NCI)
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients	NCT02670109	Triple-Negative... Residual Tumor	Carmustine Cyclophosphamid... Carboplatin Autologous Hema... Busulfan	18 Years - 60 Years	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma	NCT00504101	Multiple Myelom...	Arsenic trioxid... Bortezomib Melphalan Autologous hema...	18 Years - 70 Years	University of Miami
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00007852	Lymphoma	rituximab carmustine cytarabine etoposide melphalan autologous hema...	19 Years -	University of Nebraska
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma	NCT00567567	Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob...	Autologous Hema... Carboplatin Cisplatin Cyclophosphamid... Doxorubicin Hyd... Etoposide External Beam R... Filgrastim Isotretinoin Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Thiotepa Topotecan Hydro... Vincristine Sul...	- 30 Years	Children's Oncology Group
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	NCT03019640	Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Recurrent Indol... Refractory Diff... Refractory Foll... Refractory Indo...	Autologous Hema... Carmustine Cord Blood-deri... Cytarabine Etoposide Filgrastim Lenalidomide Melphalan Rituximab	15 Years - 70 Years	M.D. Anderson Cancer Center
Fluoroquinolone Resistance Prevalence Study	NCT05824689	Multiple Myelom...		18 Years -	Hackensack Meridian Health
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant	NCT00434629	B-cell Lymphoma Non-Hodgkin's L...	Bexxar	18 Years - 75 Years	University of Pennsylvania
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	NCT00039377	Adult Acute Lym...	imatinib mesyla... methotrexate vincristine sul... leucovorin calc... peripheral bloo... autologous hema... allogeneic hema... total-body irra... tacrolimus filgrastim etoposide cyclophosphamid... cytarabine laboratory biom...	15 Years - 59 Years	National Cancer Institute (NCI)
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)	NCT05632380	Multiple Myelom...	Autologous hema... C-CAR088	18 Years - 65 Years	Institute of Hematology & Blood Diseases Hospital, China
Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma	NCT00410631	Neuroblastoma	filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide phosp... ifosfamide isotretinoin melphalan topotecan hydro... vincristine sul... vindesine autologous hema... conventional su... peripheral bloo... iobenguane I 13... radiation thera...	- 21 Years	National Cancer Institute (NCI)
ASCT With Nivolumab in Patients With Multiple Myeloma	NCT03292263	Multiple Myelom...	Melphalan Nivolumab Autologous Stem...	18 Years - 70 Years	St. Petersburg State Pavlov Medical University
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	NCT01256398	Acute Lymphobla... Adult B Acute L...	Alemtuzumab Allogeneic Hema... Autologous Hema... Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Hy... Dexamethasone Etoposide Phosp... Filgrastim Fludarabine Pho... In Vitro-Treate... Laboratory Biom... Leucovorin Calc... Melphalan Mercaptopurine Methotrexate Pegfilgrastim Pharmacological... Tacrolimus Vincristine Sul...	18 Years -	National Cancer Institute (NCI)
Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma	NCT00892346	Multiple Myelom...	Single ASCT wit...	18 Years - 65 Years	Shanghai Jiao Tong University School of Medicine
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT01936090	DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas...	Bortezomib Total-Body Irra... Melphalan Autologous Bone... Autologous Hema... Peripheral Bloo... Laboratory Biom...	18 Years -	Mayo Clinic
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma	NCT01074060	Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi...	plerixafor filgrastim cyclophosphamid... autologous hema... laboratory biom...	18 Years - 70 Years	City of Hope Medical Center
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	NCT06022939	AL Amyloidosis	Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ...	18 Years -	SWOG Cancer Research Network
Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma	NCT05228249	Recurrent Diffu... Recurrent Diffu... Recurrent High ... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory Diff... Refractory High... Refractory Prim... Refractory Tran...	Autologous Hema... Carmustine Cytarabine Etoposide Loncastuximab T... Melphalan	18 Years -	Fred Hutchinson Cancer Center
Exercise in Pediatric Autologous Stem Cell Transplant Patients	NCT01666015	Cancer Autologous Hema...	EXERCISE (EX) Standard Care	5 Years - 18 Years	University of Calgary
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma	NCT00504101	Multiple Myelom...	Arsenic trioxid... Bortezomib Melphalan Autologous hema...	18 Years - 70 Years	University of Miami
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R	NCT00534469	Leukemia	aldesleukin filgrastim busulfan cytarabine etoposide idarubicin autologous hema... bone marrow tra... peripheral bloo... total-body irra...	16 Years - 60 Years	City of Hope Medical Center
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation	NCT02576327	Vomiting	Tropisetron Dexamethasone Aprepitant	18 Years - 65 Years	Peking University
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma	NCT03786783	Ganglioneurobla... High Risk Neuro...	Autologous Hema... Carboplatin Cisplatin Cyclophosphamid... Dexrazoxane Dinutuximab Doxorubicin Etoposide External Beam R... Isotretinoin Melphalan Sargramostim Thiotepa Topotecan Vincristine	- 30 Years	National Cancer Institute (NCI)
ASCT With Nivolumab in Patients With Multiple Myeloma	NCT03292263	Multiple Myelom...	Melphalan Nivolumab Autologous Stem...	18 Years - 70 Years	St. Petersburg State Pavlov Medical University
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases	NCT00716066	Autoimmune Dise... Neurologic Auto... Autologous Tran... Multiple Sclero... MS Stem Cell Tr... Multiple Sclero... Stiff Person Sy... HCT for Neurolo... CIDP Transplant Myasthenia Grav... Autoimmune Nerv... Central Nervous... Cerebellar Dege... Chronic Inflamm... Lambert Eaton M... Myasthenia Grav... Neuromyelitis O... Opsoclonus Myoc... Rasmussen Subac...	Anti-Thymocyte ... Autologous Hema... Carmustine Cytarabine Etoposide Laboratory Biom... Melphalan Peripheral Bloo... Prednisone Syngeneic Bone ...	- 71 Years	Fred Hutchinson Cancer Center
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	NCT06022939	AL Amyloidosis	Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ...	18 Years -	SWOG Cancer Research Network
Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT00941720	Multiple Myelom...	busulfan cyclophosphamid... autologous hema...	18 Years -	Case Comprehensive Cancer Center
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma	NCT00526318	Neuroblastoma	filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide phosp... ifosfamide isotretinoin melphalan topotecan hydro... vincristine sul... vindesine autologous hema... iobenguane I 13... radiation thera...	- 21 Years	National Cancer Institute (NCI)
Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma	NCT00569985	Lymphoma	lentivirus vect... carmustine cyclophosphamid... etoposide autologous hema...	18 Years - 60 Years	City of Hope Medical Center
Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma	NCT00091104	Melanoma (Skin)	MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra...	18 Years -	National Institutes of Health Clinical Center (CC)
Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma	NCT00566228	Lymphoma	autologous hema... leukapheresis	18 Years - 120 Years	Mayo Clinic
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma	NCT01413178	Myeloma	Busulfan Melphalan Questionnaire G-CSF High Dose Melph... Stem cell trans...	18 Years - 70 Years	M.D. Anderson Cancer Center
IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT	NCT02671708	Autologous Hema... Acute Myeloid L... Conditioning	Idarubicin（IDA） Busulfan (BU) Cyclophosphamid...	14 Years - 65 Years	Nanfang Hospital, Southern Medical University
Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT00941720	Multiple Myelom...	busulfan cyclophosphamid... autologous hema...	18 Years -	Case Comprehensive Cancer Center
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	NCT01008462	B-Cell Prolymph... Hypodiploidy Loss of Chromos... Plasma Cell Leu... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Plasm... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Non-... Refractory Plas... Refractory Smal... t(14;16) t(4;14) T-Cell Prolymph... Waldenstrom Mac...	Allogeneic Bone... Allogeneic Hema... Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra...	- 75 Years	Fred Hutchinson Cancer Center
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis	NCT06022939	AL Amyloidosis	Autologous Hema... Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Bortezomib Computed Tomogr... Cyclophosphamid... Daratumumab and... Dexamethasone Echocardiograph... Magnetic Resona... Melphalan Positron Emissi... Stem Cell Isola... Survey Administ...	18 Years -	SWOG Cancer Research Network
Fluoroquinolone Resistance Prevalence Study	NCT05824689	Multiple Myelom...		18 Years -	Hackensack Meridian Health
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma	NCT01798004	Ganglioneurobla... Stage 1 Neurobl... Stage 2 Neurobl... Stage 2A Neurob... Stage 2B Neurob... Stage 3 Neurobl... Stage 4 Neurobl... Stage 4S Neurob...	Autologous Hema... Busulfan Cisplatin Cyclophosphamid... Doxorubicin Hyd... Etoposide External Beam R... Filgrastim Laboratory Biom... Melphalan Mesna Peripheral Bloo... Pharmacological... Topotecan Hydro... Vincristine Sul...	- 30 Years	Children's Oncology Group
Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant	NCT00602706	Multiple Myelom...	sargramostim melphalan autologous hema... peripheral bloo... samarium Sm 153...	18 Years -	Mayo Clinic
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma	NCT00992446	Adult Diffuse L... B-Cell Non-Hodg... Follicular Lymp... Mantle Cell Lym... Non-Hodgkin Lym... T-Cell Non-Hodg...	Autologous Hema... Bortezomib Carmustine Cytarabine Etoposide Melphalan Rituximab Vorinostat	18 Years -	Fred Hutchinson Cancer Center
Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT01729091	Plasma Cell Leu... Plasma Cell Mye...	Autologous Hema... Elotuzumab Laboratory Biom... Lenalidomide Melphalan Natural Killer ... Umbilical Cord ...	18 Years - 75 Years	M.D. Anderson Cancer Center
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma	NCT03477539	Plasma Cell Mye...	Autologous Hema... Daratumumab Lenalidomide	18 Years -	Mayo Clinic
Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma	NCT00091104	Melanoma (Skin)	MART-1:27-35 pe... aldesleukin filgrastim incomplete Freu... therapeutic aut... therapeutic tum... cyclophosphamid... fludarabine pho... autologous hema... in vitro-treate... total-body irra...	18 Years -	National Institutes of Health Clinical Center (CC)
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant	NCT00434629	B-cell Lymphoma Non-Hodgkin's L...	Bexxar	18 Years - 75 Years	University of Pennsylvania
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia	NCT00006363	Adult Acute Bas... Adult Acute Eos... Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... de Novo Myelody... Untreated Adult... Untreated Child...	cytarabine daunorubicin hy... etoposide valspodar filgrastim busulfan autologous hema... peripheral bloo... aldesleukin clinical observ... pharmacological...	15 Years - 59 Years	National Cancer Institute (NCI)
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R	NCT00534469	Leukemia	aldesleukin filgrastim busulfan cytarabine etoposide idarubicin autologous hema... bone marrow tra... peripheral bloo... total-body irra...	16 Years - 60 Years	City of Hope Medical Center
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma	NCT02342782	Mature T-Cell a... Recurrent Matur... Refractory Matu... Recurrent Cutan... Refractory Cuta...	Yttrium Y 90 Ba... Carmustine Etoposide Cytarabine Melphalan Autologous Hema... Laboratory Biom... Pharmacological...	18 Years -	City of Hope Medical Center
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant	NCT00114101	DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult...	Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis...	18 Years - 70 Years	National Cancer Institute (NCI)
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors	NCT00432094	Childhood Germ ... Ovarian Cancer Teratoma	carboplatin etoposide ifosfamide paclitaxel thiotepa autologous hema... Mesna filgrastim	10 Years - 69 Years	Masonic Cancer Center, University of Minnesota
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma	NCT00793572	Refractory Plas...	Autologous Hema... Bortezomib Cyclosporine Cyclosporine Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Syngeneic Bone ... Total-Body Irra...	18 Years -	Fred Hutchinson Cancer Center
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma	NCT01527149	Stage I Mantle ... Stage II Contig... Stage II Non-Co... Stage III Mantl... Stage IV Mantle...	Autologous Hema... Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul...	18 Years - 70 Years	Roswell Park Cancer Institute
Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma	NCT00317408	Lymphoma	anti-thymocyte ... busulfan carboplatin carmustine cyclosporine cytarabine dexamethasone etoposide phosp... idarubicin ifosfamide leucovorin calc... lomustine melphalan methotrexate mitoxantrone hy... prednisolone thiotepa vinblastine sul... vindesine allogeneic hema... autologous hema... peripheral bloo... total-body irra...	- 21 Years	National Cancer Institute (NCI)
Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma	NCT00317408	Lymphoma	anti-thymocyte ... busulfan carboplatin carmustine cyclosporine cytarabine dexamethasone etoposide phosp... idarubicin ifosfamide leucovorin calc... lomustine melphalan methotrexate mitoxantrone hy... prednisolone thiotepa vinblastine sul... vindesine allogeneic hema... autologous hema... peripheral bloo... total-body irra...	- 21 Years	National Cancer Institute (NCI)
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT00938626	Multiple Myelom...	anti-CD3 x anti... autologous hema... peripheral bloo...	18 Years -	Barbara Ann Karmanos Cancer Institute
Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT01842308	DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas...	Autologous Bone... Autologous Hema... Carfilzomib Laboratory Biom... Melphalan	18 Years -	Mayo Clinic
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma	NCT02443077	Recurrent Diffu... Refractory Diff...	Autologous Bone... Autologous Hema... Carmustine Cyclophosphamid... Cytarabine Etoposide Ibrutinib Laboratory Biom... Melphalan Pharmacogenomic... Placebo Adminis...	18 Years -	National Cancer Institute (NCI)
CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma	NCT03579927	CD19 Positive Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Refractory B-Ce... Refractory Diff... Refractory Foll...	Autologous Hema... Carmustine Cytarabine Etoposide Filgrastim Melphalan Rituximab Umbilical Cord ...	18 Years - 70 Years	M.D. Anderson Cancer Center
Helical Tomotherapy in Multiple Myeloma	NCT05970198	Multiple Myelom...	Total Marrow ir... Autologous hema...	18 Years - 75 Years	Zhongnan Hospital
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	NCT01815749	Adult Grade III... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Post-transplant... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	autologous CD19... autologous hema... laboratory biom...	18 Years -	City of Hope Medical Center
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma	NCT03440567	Recurrent Diffu... Recurrent Mantl... Refractory Diff... Refractory Mant... Transformed Fol...	Autologous Hema... Avelumab Carboplatin Etoposide Phosp... Ibrutinib Ifosfamide Laboratory Biom... Rituximab Utomilumab	18 Years -	City of Hope Medical Center
Haplo-SCT vs ASCT With or Without Decitabine in AML CR1	NCT02059720	Acute Myeloid L...	HSCT	18 Years -	The First Affiliated Hospital of Soochow University
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)	NCT05632380	Multiple Myelom...	Autologous hema... C-CAR088	18 Years - 65 Years	Institute of Hematology & Blood Diseases Hospital, China
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma	NCT03202628	Recurrent Plasm... Refractory Plas...	Autologous Hema... Dexamethasone Ixazomib Citrat... Laboratory Biom... Pomalidomide	18 Years -	Mayo Clinic
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	NCT01815749	Adult Grade III... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Post-transplant... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	autologous CD19... autologous hema... laboratory biom...	18 Years -	City of Hope Medical Center
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma	NCT00554788	Extraocular Ret...	Autologous Bone... Autologous Hema... Carboplatin Cisplatin Cyclophosphamid... Etoposide Filgrastim In Vitro-Treate... Radiation Thera... Thiotepa Vincristine Sul...	- 10 Years	Children's Oncology Group
Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma	NCT00003954	Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi...	melphalan autologous hema... autologous bone... peripheral bloo... total-body irra... peripheral bloo... cyclosporine mycophenolate m... therapeutic all...	- 65 Years	Fred Hutchinson Cancer Center
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma	NCT01798004	Ganglioneurobla... Stage 1 Neurobl... Stage 2 Neurobl... Stage 2A Neurob... Stage 2B Neurob... Stage 3 Neurobl... Stage 4 Neurobl... Stage 4S Neurob...	Autologous Hema... Busulfan Cisplatin Cyclophosphamid... Doxorubicin Hyd... Etoposide External Beam R... Filgrastim Laboratory Biom... Melphalan Mesna Peripheral Bloo... Pharmacological... Topotecan Hydro... Vincristine Sul...	- 30 Years	Children's Oncology Group
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma	NCT00992446	Adult Diffuse L... B-Cell Non-Hodg... Follicular Lymp... Mantle Cell Lym... Non-Hodgkin Lym... T-Cell Non-Hodg...	Autologous Hema... Bortezomib Carmustine Cytarabine Etoposide Melphalan Rituximab Vorinostat	18 Years -	Fred Hutchinson Cancer Center
Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma	NCT00960739	Neuroblastoma	Topotecan hydro... Autologous hema... iobenguane I 13... total-body irra...	1 Year - 20 Years	Centre Oscar Lambret
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma	NCT05432635	B-Cell Non-Hodg... Diffuse Large B... Mantle Cell Lym... Recurrent B-Cel... Recurrent Diffu... Recurrent Mantl... Recurrent Trans... Transformed Non...	Anti-CD19-CAR C... Autologous Hema... Multi-peptide C... Myeloablative C...	18 Years -	City of Hope Medical Center
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma	NCT03440567	Recurrent Diffu... Recurrent Mantl... Refractory Diff... Refractory Mant... Transformed Fol...	Autologous Hema... Avelumab Carboplatin Etoposide Phosp... Ibrutinib Ifosfamide Laboratory Biom... Rituximab Utomilumab	18 Years -	City of Hope Medical Center
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	NCT03019640	Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Recurrent Indol... Refractory Diff... Refractory Foll... Refractory Indo...	Autologous Hema... Carmustine Cord Blood-deri... Cytarabine Etoposide Filgrastim Lenalidomide Melphalan Rituximab	15 Years - 70 Years	M.D. Anderson Cancer Center
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	NCT00005803	Prolymphocytic ... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Non-H... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... T-Cell Chronic ... T-Cell Prolymph...	Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cyclosporine Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Therapeutic Aut... Total-Body Irra...	- 75 Years	Fred Hutchinson Cancer Center
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia	NCT00416598	Acute Myeloid L... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Untreated Adult...	Autologous Bone... Autologous Hema... Busulfan Cytarabine Daunorubicin Hy... Decitabine Etoposide Filgrastim Laboratory Biom... Pharmacological...	15 Years - 59 Years	National Cancer Institute (NCI)
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma	NCT06245629	Myeloma Multipl...	Bortezomib-bend...	18 Years -	Uppsala University
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma	NCT00793572	Refractory Plas...	Autologous Hema... Bortezomib Cyclosporine Cyclosporine Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Syngeneic Bone ... Total-Body Irra...	18 Years -	Fred Hutchinson Cancer Center
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas	NCT00669669	Glioblastoma Gliosarcoma	3-Dimensional C... Autologous Hema... Carmustine Filgrastim In Vitro-Treate... Intensity-Modul... Laboratory Biom... O6-Benzylguanin... Plerixafor Proton Beam Rad... Temozolomide	18 Years -	Fred Hutchinson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: